The latest version of iClinica 4G facilitates collaboration among all study parties, and delivers unparalleled transparency, accountability and efficiency in the conduct of cardiac studies.
Rochester, NY (PRWEB) May 14, 2013
iCardiac Technologies, Inc., a leading provider of cardiac safety assessment services, announced today the release of an enhanced version of its advanced ECG clinical trial management platform, iClinica 4G. Through its new module, StudyView, the platform now allows pharmaceutical sponsors, CROs and investigative sites to comprehensively monitor the status of global cardiac safety studies online and in real time via a flexible and easy-to-use dashboard.
“iCardiac has a proud history as a technology leader in the cardiac safety industry,” said Mikael Totterman, chief executive officer of iCardiac. “This new release of iClinica 4G reflects that continued leadership and will be of particular value to our clients, CRO partners and investigative sites in tracking critical information within global, multi-site clinical trials.”
Added Thuan Pham, director of software development at iCardiac, “The latest version of iClinica 4G facilitates collaboration among all study parties, and delivers unparalleled transparency, accountability and efficiency in the conduct of cardiac studies.”
iCardiac Technologies is a global provider of cardiac safety services. The company was built upon over 30 years of cardiology and drug safety research and now provides services to 7 of the largest 10 pharmaceutical companies in the world, as well as to many small and mid-sized companies. Its reach is international, working with clinics all over the world to bring the best results to cardiac safety. Learn more at http://www.icardiac.com.